Treatment with the PPP inhibitor 6-aminonicotinamide (6-AN) abrogated the growth of Keap1-deficient tumor cells, suggesting a potential therapeutic approach to target this subset of KRAS-mutant LUAD cancers. Here, KRAS is linked to neoplasm.